Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
about
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Preclinical development of G1T ...... with CDK4/6 sensitive tumors.
@en
type
label
Preclinical development of G1T ...... with CDK4/6 sensitive tumors.
@en
prefLabel
Preclinical development of G1T ...... with CDK4/6 sensitive tumors.
@en
P2093
P2860
P356
P1433
P1476
Preclinical development of G1T ...... with CDK4/6 sensitive tumors.
@en
P2093
David D Darr
Francis X Tavares
Jamie L Jordan
Jay C Strum
Jessica A Sorrentino
John E Bisi
Patrick J Roberts
P2860
P304
42343-42358
P356
10.18632/ONCOTARGET.16216
P407
P577
2017-03-15T00:00:00Z